作者: Davette L. Behrens , Frank W. Perrella , Shih-Fong Chen , Lisa M. Papp
DOI:
关键词:
摘要: Abstract The novel anticancer drug candidate brequinar sodium (DuP 785, NSC 368390, 6-fluoro-2-(2′-fluoro-1,1′-biphenyl-4-yl)-3-methyl-4-quinoline-carboxylic acid salt) was shown previously to be an inhibitor of dihydroorotate dehydrogenase, the fourth enzyme de novo pyrimidine biosynthetic pathway. Brequinar inhibits activity this isolated from mammalian sources only but not those forms yeast or bacteria, which also use ubiquinone as cofactor. does inhibit a soluble Zymobacterium oroticum dehydrogenase uses NAD+ L1210 with mixed inhibition kinetics respect either substrate (dihydroorotate) cofactor (ubiquinone Q6) K1′ values in 5–8 nm range. Our results suggest that by binding at unique site is distinct ubiquinone-binding site. This appears enzyme, because yeast, Escherichia coli, Z. enzyme.